<code id='0BBDF8DB4E'></code><style id='0BBDF8DB4E'></style>
    • <acronym id='0BBDF8DB4E'></acronym>
      <center id='0BBDF8DB4E'><center id='0BBDF8DB4E'><tfoot id='0BBDF8DB4E'></tfoot></center><abbr id='0BBDF8DB4E'><dir id='0BBDF8DB4E'><tfoot id='0BBDF8DB4E'></tfoot><noframes id='0BBDF8DB4E'>

    • <optgroup id='0BBDF8DB4E'><strike id='0BBDF8DB4E'><sup id='0BBDF8DB4E'></sup></strike><code id='0BBDF8DB4E'></code></optgroup>
        1. <b id='0BBDF8DB4E'><label id='0BBDF8DB4E'><select id='0BBDF8DB4E'><dt id='0BBDF8DB4E'><span id='0BBDF8DB4E'></span></dt></select></label></b><u id='0BBDF8DB4E'></u>
          <i id='0BBDF8DB4E'><strike id='0BBDF8DB4E'><tt id='0BBDF8DB4E'><pre id='0BBDF8DB4E'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:explore    Page View:4
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In